MUKTESAR, FOR THE YEAR ENDING THE 31ST MARCH, 1929
9
(4) Anthrax serum. Issued 40,033 (15 c. c.) doses, as compared
with 48,155 doses in 1927-28. Manufactured 37,507 doses, as
compared with nil doses in the preceding year. Stock in hand at the
commencement of the year 22,321 doses; at close, 19,795 doses.
(5) Blackquarter serum. Issued 83,953 (15 c. c.) doses, as
compared with 38,669 doses in 1927-28. Manufactured 1,02,400 doses
as against 69,506 doses in the previous year. Stock in hand at the
commencement of the year 31,989 doses ; at close, 50,436.
(6) Blackquarter aggressin. Issued 2,22,419 (5 c. c.) doses of
" aggressin ", as compared with 1,33,401 doses in 1927-28. Manufac-
tured 2,34,200 doses as against 1,39,600 doses in the previous year. Stock
in hand at the commencement of the year, 8,249 doses; at close, 20,030
doses. The large increase in this relatively newly introduced product is
a cause for considerable satisfaction, indicating its efficacy and the
confidence of consumers in its use in the " field ".
(7) Mallein. (a) Issued 18,089 (1 c. c.) doses of mallein for the
ordinary subcutaneous test for glanders, as compared with 38,469 doses
in 1927-28. (b) Issued 16,220 (0.1 c.c.) doses for the intrapalpebral
(I. D. P.) test, as compared with 51,660 doses in 1927-28. There were
in stock 1,517 doses of ordinary and (40,055 doses of I. D. P. mallein
at the commencement of the year, and 25,389 doses of ordinary and)
1,13,570 doses of I. D. P. mallein at the close. Manufactured 42,061
doses for the ordinary and 89,735 doses for the I. D. P. test, as against
22,500 and 33,310 doses, respectively, in the previous year.
(8) Tuberculin. (a) Issued 338 (3 c. c.) doses of ordinary (human)
(tuberculin for the subcutaneous test for tuberculosis, and 985 doses
0.25 c. c.) of concentrated (human) tuberculin for the intrapalpebral and
double-intradermal tests for the disease, as compared with 893 and 5,150
doses, respectively, in 1927-28. (b) Issued 403 (8 c. c.) doses of ordi-
nary avian tuberculin for the subcutaneous test, and 540 (0.25 c. c.) doses
of concentrated avian tuberculin for the intrapalpebral and double-
intradermal tests for Johne's disease, as compared with 36 and 6,085
doses, respectively, in 1927-28. Manufactured 540 doses of concentrated
(human) tuberculin, and 400 doses of concentrated (avian) tuberculin.
At the commencement of the year there were available 2,126 doses of
ordinary (human), 9,205 doses of concentrated (human), 1,388 doses
of ordinary (avian) and 8,480 doses of concentrated (avian) tubercul-
in ; and at the close 1,788, 9,010, 985 and 8,600 doses, respectively.
(9) Strangles serum and vaccine. Issued 1,239 (15 c.c.) doses of anti-
streptococcic serum and 1,133 doses of anti-streptococcic vaccine, as
against 1,118 doses of serum and 561 doses of vaccine in 1927-28. One
thousand one hundred and fifty-two doses of vaccine were prepared
during the year. Since these products have been found, as the result of
extensive research work, to be of no value in the protection of equines
against the specific disease strangles, it is proposed in future to discon-
tinue the manufacture and issue of anti-streptococcic serum entirely.
There is still a small demand, however, for anti-streptococcic vaccine.
(10) Contagious abortion (equine) vaccine. One hundred and 20 doses
of Bacillus abortivo-equinus vaccine were prepared and issued during